- Scope of the procurement
- Lot 1. Diabetic Eye Screening Programme for Cornwall and Isles of Scilly
- Lot 2. Diabetic Eye Screening Programme for Devon
- Lot 3. Diabetic Eye Screening Programme for Somerset
- Lot 4. Diabetic Eye Screening Programme for Gloucestershire
- Lot 5. Diabetic Eye Screening Programme for Bristol, North Somerset and South Gloucestershire (BNSSG)
Section one: Contracting authority
one.1) Name and addresses
NHS England
Three-Six-Zero - 360, Marlborough Street
Bristol
BS1 3NX
Contact
Hannah Morley
Country
United Kingdom
Region code
UKK11 - Bristol, City of
Justification for not providing organisation identifier
Not on any register
Internet address(es)
Main address
https://www.england.nhs.uk/south/
Buyer's address
https://health-family.force.com/s/Welcome
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://health-family.force.com/s/Welcome
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
NHS England South West - Diabetic Eye Screening Programmes for Cornwall, Devon, Somerset, Gloucestershire and Bristol, North Somerset, South Gloucestershire (BNSSG)
Reference number
C185632
two.1.2) Main CPV code
- 85000000 - Health and social work services
two.1.3) Type of contract
Services
two.1.4) Short description
NHSE South West (The Commissioner) seeks to re-commission five Diabetic Eye Screening Programmes (DESP) to deliver screening to the eligible populations of Cornwall and Isles of Scilly (Lot 1), Devon (Lot 2), Somerset (Lot 3), Gloucestershire (Lot 4), and Bristol, North Somerset and South Gloucestershire (BNSSG) (Lot 5).
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contracts are due to commence on 1st April 2024.
The 9 year estimated contract values, based on predicted activity levels, are:
Lot 1 = £9,588,607
Lot 2 = £24,522,731
Lot 3 = £13,581,836
Lot 4 = £11,231,506
Lot 5 = £15,468,533
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
This procurement is being carried out by NHS South, Central and West Commissioning Support Unit (SCW) on behalf of the Commissioners.
Interested providers will be able to view the opportunity and access the tender documentation via the 'Live Opportunities' list on the e-procurement system, Atamis, available on the following link: https://health-family.force.com/s/Welcome
two.1.5) Estimated total value
Value excluding VAT: £74,393,213
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for all lots
two.2) Description
two.2.1) Title
Diabetic Eye Screening Programme for Cornwall and Isles of Scilly
Lot No
1
two.2.2) Additional CPV code(s)
- 85000000 - Health and social work services
two.2.3) Place of performance
NUTS codes
- UKK3 - Cornwall and Isles of Scilly
two.2.4) Description of the procurement
NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Cornwall and Isles of Scilly.
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.
The 9 year estimated contract value, based on predicted activity levels, is £9,588,607.
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
two.2.6) Estimated value
Value excluding VAT: £9,588,607
two.2.7) Duration of the contract or the framework agreement
Duration in months
108
two.2.14) Additional information
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
two.2) Description
two.2.1) Title
Diabetic Eye Screening Programme for Devon
Lot No
2
two.2.2) Additional CPV code(s)
- 85000000 - Health and social work services
two.2.3) Place of performance
NUTS codes
- UKK4 - Devon
two.2.4) Description of the procurement
NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Devon.
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.
The 9 year estimated contract value, based on predicted activity levels, is £24,522,731.
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
two.2.6) Estimated value
Value excluding VAT: £24,522,731
two.2.7) Duration of the contract or the framework agreement
Duration in months
108
two.2.14) Additional information
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
two.2) Description
two.2.1) Title
Diabetic Eye Screening Programme for Somerset
Lot No
3
two.2.2) Additional CPV code(s)
- 85000000 - Health and social work services
two.2.3) Place of performance
NUTS codes
- UKK23 - Somerset
two.2.4) Description of the procurement
NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Somerset.
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.
The 9 year estimated contract value, based on predicted activity levels, is £13,581,836.
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
two.2.6) Estimated value
Value excluding VAT: £13,581,836
two.2.7) Duration of the contract or the framework agreement
Duration in months
108
two.2.14) Additional information
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
two.2) Description
two.2.1) Title
Diabetic Eye Screening Programme for Gloucestershire
Lot No
4
two.2.2) Additional CPV code(s)
- 85000000 - Health and social work services
two.2.3) Place of performance
NUTS codes
- UKK13 - Gloucestershire
two.2.4) Description of the procurement
NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Gloucestershire.
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.
The 9 year estimated contract value, based on predicted activity levels, is £11,231,506.
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
two.2.6) Estimated value
Value excluding VAT: £11,231,506
two.2.7) Duration of the contract or the framework agreement
Duration in months
108
two.2.14) Additional information
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
two.2) Description
two.2.1) Title
Diabetic Eye Screening Programme for Bristol, North Somerset and South Gloucestershire (BNSSG)
Lot No
5
two.2.2) Additional CPV code(s)
- 85000000 - Health and social work services
two.2.3) Place of performance
NUTS codes
- UKK1 - Gloucestershire, Wiltshire and Bristol/Bath area
two.2.4) Description of the procurement
NHSE South West (The Commissioner) seeks to re-commission a Diabetic Eye Screening Programme (DESP) to deliver screening to the eligible population of Bristol, North Somerset and South Gloucestershire (BNSSG).
The eligible population includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with, a GP in the lot area, as well as individuals within prisons, secure units and the armed forces.
The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment, if necessary, of sight threatening diabetic retinopathy.
This will be achieved by delivering an evidence-based service that:
•Identifies the eligible population and ensures effective delivery with maximum coverage
•Is safe, effective, high quality, externally and independently monitored, and quality assured
•Leads to earlier detection, appropriate referral, effective treatment and improved outcomes
•Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes
•Has audit embedded in the service
•Works effectively with other stakeholders to ensure the care pathway is smooth and efficient
There are 3 key elements of service delivery, namely:
•Call/recall for all people with diabetes invited for routine digital screening; this is currently undertaken on an annual basis, but screening intervals are likely to extend to 2 years for people at low risk during the contract term, in line with national guidance
•Digital surveillance where individuals need more frequent screening
•Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).
Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.
The Services will be commissioned using the national service specification for DESP Services, localised where appropriate.
The Contract term will be 6 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner. The Contract is due to commence on 1st April 2024.
The 9 year estimated contract value, based on predicted activity levels, is £15,468,533.
The Contract will operate on a hybrid basis with a fixed "block" element based upon the actual activity for routine screening in 2021/2022 plus a variable element for digital surveillance and SLB and a further variable element to incentivise uptake to 85%. Variable elements will be paid according to activity undertaken.
The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).
National changes to screening frequency for low risk individuals are expected to be implemented during the contract term which will have an impact on activity. The subsequent impact on contract values will be agreed between the Provider and the Commissioner via contract variation.
two.2.6) Estimated value
Value excluding VAT: £15,468,533
two.2.7) Duration of the contract or the framework agreement
Duration in months
108
two.2.14) Additional information
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
Section four. Procedure
four.1) Description
four.1.1) Form of procedure
Open procedure
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2023/S 000-009618
four.2.2) Time limit for receipt of tenders or requests to participate
Date
8 August 2023
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
Section six. Complementary information
six.3) Additional information
Interested providers will be able to view the opportunity and access the tender documentation via the 'Live Opportunities' list on the 'Health Family' e-procurement system, Atamis. Click on 'View our Live Opportunities' from the home page, available on the following link: https://health-family.force.com/s/Welcome.
Once you have found the opportunity (via the search function, using the title or reference number), to gain full access to the tender documentation (including questionnaires), you will need to click on 'Register interest' - this will take you to the log-in page.
If you are not already registered on the system, you will need to do so before gaining full access to the documentation and be able to submit a bid.
The services are healthcare services falling within Schedule 3 to the Public Contracts Regulations 2015 ("the Regulations") which are not subject to the full regime of the Regulations, but are instead governed by the "Light Touch Regime" contained within Chapter 3, Section 7 of the Regulations (Regulations 74 to 77).
The tendering process will be conducted in accordance with the requirements and flexibilities provided by Articles 74 to 76 of the Directive, and Regulations 74 to 76 of the Regulations. The Authority will run a transparent tender process, treating all Bidders equally. For the avoidance of doubt, the Authority will not be bound by the Regulations or any other regulations or legislation except for the specific parts or circumstances that apply to the procurement of these Services.
Neither the inclusion of a Bidder selection stage, nor the use of any language or terms found in the Directive or Regulations, nor the description of the procedure voluntarily adopted by the Authority ("Open", "Restricted", "Competitive Procedure with Negotiation", "Competitive Dialogue" or any other description), nor any other indication, shall be taken to mean that the Authority intends to hold itself bound by the Directive or Regulations, save by the provisions applicable to services coming within the scope of Annex XIV of the Directive / Schedule 3 of the Regulations.
The Contracting Authority intends to voluntarily observe the award decision notices provisions and 10 day standstill period described in Regulation 87 of the Regulations.
six.4) Procedures for review
six.4.1) Review body
High Court in London
London
Country
United Kingdom